Business
Marijuana, Inc., Completes Acquisition of Exousia AI and Enters Expanding Exosome Market
Marijuana, Inc., Completes Acquisition of Exousia AI and Enters Expanding Exosome Market.
About this update from Marijuana Inc.
[{"type":"text","content":"\n\n\n\nMarijuana, Inc., Completes Acquisition of Exousia AI and Enters Expanding Exosome Market\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nMarijuana, Inc., Completes Acquisition of Exousia AI and Enters Expanding Exosome Market\nPR Newswire\nST. PETERSBURG, Fla., Jan. 6, 2025\n\n\n\n-          Pursing commercial applications in skincare serving a growing market of $310 million\nST. PETERSBURG, Fla., Jan. 6, 2025 /PRNewswire/ -- Marijuana, Inc. (OTCPINK: MAJI), dba Exousia Pro, Inc., has acquired 100% of Exousia AI in a cash and stock transaction from Ludwig Enterprises, Inc. Exousia Pro will issue 47,000,000 million restricted shares of its Common stock to Ludwig Enterprises.\n\nThe 47,000,000 shares being issued are restricted shares with certain lock-up features. The legend cannot be removed until six months AFTER Exousia Pro has completed its up-listing with NASDAQ or an equivalent exchange.  The Company further agreed to assume liabilities under $75,000 and issued Ludwig a Note for $100,000.\nExousia AI is a leading USA-based biotechnology company in the field of Exosomes. The Company secured a worldwide license for its Exosome technology. The technology covers growing and extracting plant-based exosomes and loading them for use as a drug delivery system. The loading process can also be applied to human-derived exosomes. The acquisition includes an ongoing study on using Exosomes to treat Glioblastoma (\"GBM\"). The study is well underway, with very promising initial findings.  Exousia AI is involved in other studies, including one study concluding in Italy.  Exousia Pro will enter two additional studies covering dermatology and the dental market that are part of the acquisition. \nExousia Pro will manufacture and sell vials of wet exosomes or jars of dried exosomes to the nutraceutical and dermatology markets.  The OTC exosome market, known as cosmeceuticals, is rapidly expanding due to consumer demand for antiaging and regenerative skincare solutions.  A 30-day treatment for skin ...